Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, remains a major clinical challenge owing to its complex pathophysiology and clinical management: it is a ...

IBD, inflammatory bowel disease. SCFA, Short-Chain Fatty Acids; LPS, Lipopolysaccharide; IL-6, Interleukin-6; IL-8, Interleukin-8; IL-10, Interleukin-10; IL-12 ...

Broad-spectrum antibiotics will alter the composition of the human gut microbiome, with transiently reduced bacterial diversity. Thus, it is reasonable to hypothesize that antibiotic-induced ...

Investigating the relationship between IL-1 and inflammation in inflammatory bowel disease (IBD), researchers unveiled mesenchyme homeobox 1 (MEOX1), an IL-1-dependent transcription factor that is ...

Inflammatory bowel disease (IBD) encompasses a spectrum of disorders characterized by chronic inflammation of the digestive tract, driven in part by a dysregulated immune response to the gut ...

mTOR, mammalian target of rapamycin; p70S6K, The 70kDa ribosomal S6 kinase 1; NLRP3, NOD-like receptor thermal protein domain associated protein 3; ASC, apoptosis-associated speck-like protein ...

Inflammatory Bowel Disease (IBD), encompassing ulcerative colitis (UC) and Crohn's disease (CD), is a chronic inflammatory condition of the gastrointestinal tract with a rising global burden.

Inflammatory bowel disease (IBD) phenotype varies by race, but regardless of race, individuals born outside the United States develop IBD at later ages and have less aggressive disease, new data ...

Despite an expanding therapeutic armamentarium, remission rates in inflammatory bowel disease (IBD) appear to plateau at 30–50% after 1 year of treatment, leading to the concept of a therapeutic ...

Data highlight both SER-603’s rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based ...

Research into GLP-1 medications and IBD is still at an early stage, and gastroenterologists aren't recommending that they be used outside their FDA-approved indications such as obesity and type 2 ...